Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRICO Phase II Irinotecan After Combined Immunotherapy in ED-SCLC
jRCTs071210090Phase 2Active, not recruiting
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan in small cell lung cancer (SCLC) (3 arms). Primary endpoint: Response rate. Started Nov 2021; status: active, not recruiting.
02
Drugs
irinotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCTs071210090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071210090.